Abstract
Background: Modified high-dose dual therapy (mHDDT), consisting of a proton pump inhibitor and amoxicillin, utilizes fewer drugs while maintaining efficacy for H. pylori eradication, particularly in regions with low amoxicillin resistance.
Objectives: (1) To evaluate the eradication efficacy of the mHDDT regimen and compare it with the bismuth-containing quadruple therapy (RBMT) in patients with H. pylori-infected gastroduodenal diseases; (2) To investigate the adverse effects and the level of treatment compliance among the patients.
Materials and Methods: A prospective comparative study was conducted at the University of Medicine and Pharmacy Hospital, Hue University, from April 2022 to August 2023. A total of 103 H. pylori-infected patients were randomly assigned to either the mHDDT group or the RBMT group.
Results: Based on intention-to-treat analysis, the eradication rates were 80.0% for the mHDDT group and 81.1% for the RBMT group (p = 0.810). Per-protocol analysis showed rates of 81.6% and 86.0%, respectively (p = 0.555). Notably, the incidence of adverse events was significantly lower in the mHDDT group (30.6%) compared to the RBMT group (84.0%) (p < 0.001). Treatment adherence was higher in the mHDDT group (91.8% vs. 78.0%), although this difference did not reach statistical significance (p = 0.055).
Conclusion: The mHDDT regimen is a simple treatment option, offering comparable efficacy to RBMT for H. pylori eradication and improvements in clinical symptoms and gastroduodenal mucosal healing with significantly fewer side effects.
| Published | 2026-06-28 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 3 (2026) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2026.3.931 | |
| Keywords |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Hue Journal of Medicine and Pharmacy
a học Tiêu hóa Việt Nam 2018, IX(53): 3284-3293.
Nguyễn Thị Hiền. Nghiên cứu hiệu quả tiệt trừ Helicobacter pylori của phác đồ 2 thuốc liều cao Rabeprazole và Amoxicillin 14 ngày ở bệnh nhân bị viêm dạ dày mạn [Luận Án Chuyên Khoa Cấp II], Huế: Đại học Y Dược Huế; 2017
Öztürk K. et al. High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection. Turk J Gastroenterol 2020, 31(3): 234-238.
Zhu Y. J., Zhang Y., Wang T. Y., Zhao J. T., et al. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therap Adv Gastroenterol 2020, 13: 1756284820937115
Nam T Phan, Long H Truong. Effectiveness of 14-day high-dose dual therapy for Helicobacter pylori infection in Vietnam. Journal of Infection in Developing Countries 2025; 19(3):404-408
Chen Li-Wei et al. The Application of High-Dose Proton Pump Inhibitor Induction Treatment before Dual Therapy for Helicobacter pylori Eradication: An Open-Label Random Trial. Journal of Clinical Medicine 2021, 10: 4352.
Bộ Y tế, Dược thư quốc gia Việt Nam. Nhà xuất bản Y Học; 2018; 188-191, 1228-1230.
Phan T. N. et al. High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam. Int J Antimicrob Agents 2015, 45(3): 244-248.
Zhou Ben-Gang et al. High-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis. Therapeutic Advances in Gastroenterology 2023, 16.
Hồ Tấn Phát và cộng sự. Đánh giá hiệu quả của phác đồ 2 thuốc liều cao ở bệnh nhân nhiễm Helicobacter pylori đã thất bại điều trị trước đó tại Bệnh viện Chợ Rẫy. Y Học TP Hồ Chí Minh 2021, 25(3): 133-140.
Yang-Jie Zhu et al. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therapeutic Advances in Gastroenterology 2020, 13.